Shareholders that lost money on Corcept Therapeutics Incorporated(CORT) should contact Levi ...
NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Corcept ...
Corcept Therapeutics initiates Momentum trial to treat resistant hypertension
Corcept Therapeutics (CORT) announced the initiation of MOMENTUM, a clinical trial examining the prevalence of endogenous ...
ETF Daily News1 个月
Corcept Therapeutics (CORT) Expected to Announce Quarterly Earnings on Thursday
Corcept Therapeutics has a one year low of $20.84 and a one year high of $74.61. The firm has a market cap of $7.62 billion, a P/E ratio of 57.71 and a beta of 0.58. 10 Stocks to Sell NOW!